PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions

News provided by

Jan 24, 2024, 03:00 ET

Eli Lilly and Company, Santec Holdings Corporation participated in the round

TOKYO, Jan. 24, 2024 /PRNewswire/ -- TOKYO, Jan. 24, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced a 1.5 billion yen ($10.3M) fundraise. Funds will be used to refine PRISM's proprietary PepMetics® chemistry platform, expand biology and screening capabilities and advance internal pipeline of PPI inhibitors.

As the numbers of so called "druggable" targets are dwindling, pharma is gradually turning to PPI targets. Due to frequent involvement in the disease and a sheer number of PPIs, they have long been recognized as a new frontier for drug discovery but the progress has been hampered by the lack of chemistries that can successfully address PPI targets. PRISM BioLab has early recognized the importance of PPIs as drug targets and has spent over a decade developing proprietary PepMetics® chemical scaffolds that mimic three-dimensional structure of the alpha-helix and beta-turn, peptide structures commonly found in PPI interphases. Today, PepMetics® chemistry enables systematic and reproducible discovery and development of drugs targeting PPIs.

"We are confident that our PepMetics® chemistry will become one of the key technologies for the PPI target field," said Dai Takehara, CEO of PRISM BioLab. "The funds from this financing round will be used to integrate our PepMetics® chemistry, biology and screening capabilities, to advance our internal pipeline, and to provide greater value to our existing and future pharma partners. We recognize the importance of partnerships for the success of new approaches to drug discovery and are fortunate to build a long-term relationship with Lilly, a top pharma company, as we move the field forward."

Comments from investors

Santec Holdings Corporation Executive Vice President & CTO Changho Chong Ph.D.

We feel confident that PRISM BioLab's promising and unique approach to drug discovery will lead to breakthrough therapeutic drugs that were previously unattainable. Santec is engaged in the development of medical imaging devices and early diagnosis utilizing Photonics. We believe that the advancement of these technologies, in conjunction with innovative drug discovery techniques, is pivotal for the comprehensive improvement of patients' Quality of Life (QoL).

About PRISM BioLab

PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics.

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceuticals Co., Ltd. are in clinical development for cancer and liver disease, respectively.

www.prismbiolab.com

SOURCE PRISM BioLab Co., Ltd.